A number of equities analysts have recently issued reports on LUNG shares. Morgan Stanley started coverage on Pulmonx in a research note on Monday, March 10th. They set an "equal weight" rating for the company. Jefferies Financial Group started coverage on Pulmonx in a research report on Monday, March 10th. They set a "buy" rating for the company. Canaccord Genuity Group lowered their target price on shares of Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Piper Sandler reiterated an "overweight" rating and issued a $9.00 price target (down from $10.00) on shares of Pulmonx in a report on Thursday, May 1st. Finally, Citigroup decreased their price objective on Pulmonx from $6.50 to $4.15 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock.